Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes (STAR1)
Type 1 Diabetes
About this trial
This is an interventional treatment trial for Type 1 Diabetes focused on measuring Diabetes, Continuous Glucose Monitoring, Glycemic Control
Eligibility Criteria
Inclusion Criteria: Age 12 - 80 years Type 1 Diabetes Mellitus diagnosed at least 1 year ago Using insulin infusion pump for past 6 months minimum Performing minimum 4 blood glucose tests per day Agree to treat to A1c targets Read and understand English Exclusion Criteria: Pregnant or planning pregnancy History of unresolved tape allergy or skin conditions
Sites / Locations
- Children's Hospital of Los Angeles
- Stanford University
- Atlanta Diabetes Associates
- Joslin Diabetes Center
- The Endocrine Group
- Diabetes and Glandular Diabetes Research Associates
- University of Washington
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Paradigm 722 sensor augmented pump
Paradigm 715 insulin pump
subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin